Galectin 3: A new player in the pathogenesis of Parkinson’s disease

QR Code

Galectin 3: A new player in the pathogenesis of Parkinson’s disease

Saved in:

Bibliographic Details
Main Authors:	Juan García-Revilla, Jose Luis Venero, José A. Rodríguez-Gómez
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2026-03-01
Series:	Neural Regeneration Research
Online Access:	https://journals.lww.com/10.4103/NRR.NRR-D-24-01410
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Etiology and Pathogenesis of Parkinson’s Disease
by: Hatano, Taku, et al.
Published: (2011)

Galectin-3 in heart recipients
by: A. A. Ulybysheva, et al.
Published: (2019-07-01)

Galectins, antibodies to them and galectin-3 binding protein in systemic lupus erythematosus
by: L. V. Kondratyeva, et al.
Published: (2025-03-01)

Determinants of alpha-synuclein pathogenesis in Parkinson’s disease
by: Oriol Bárcenas, et al.
Published: (2026-04-01)

GUT ENTEROBIOTA — A NEW PLAYER IN ATHEROSCLEROSIS PATHOGENESIS
by: L. V. Egshatyan, et al.
Published: (2014-12-01)

The role of galectin-1 and galectin-3 in the mechanisms of T-cell immune response dysregulation in colon cancer
by: V. S. Poletika, et al.
Published: (2020-10-01)

Galectin-3 in heart transplant rejection and fibrosis
by: O. P. Shevchenko, et al.
Published: (2019-10-01)

The Role of the Neuropeptide Substance P in the Pathogenesis of Parkinson’s Disease
by: Thornton, Emma, et al.
Published: (2012)

Human Parechoviruses, New Players in the Pathogenesis of Viral Meningitis
by: Benschop, Kimberley, et al.
Published: (2012)

Cyclin-Dependent Kinase 5 – An Emerging Player in Parkinson’s Disease Pathophysiology
by: Cheung, Zelda H., et al.
Published: (2012)

Galectin-1 and Galectin-3 expression in colon cancer and its correlation with tumor invasion, differentiation, and metastatic spread
by: Yu. V. Kolobovnikova, et al.
Published: (2021-12-01)

Galectin-1 in Cardiovascular Pathogenesis: Unraveling Dual Roles and Mechanistic Insights in Emerging Research
by: Po-Yuan Chen, et al.
Published: (2025-05-01)

Neuropsychological Deficits in Initial Parkinson’s Disease
by: Fernandez, Raquel Rodriguez, et al.
Published: (2011)

GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME
by: O. M. Drapkina, et al.
Published: (2015-09-01)

Galectin-3 in the blood serum of patients with bone tumors
by: N. E. Kushlinskii, et al.
Published: (2023-07-01)

Galectin-3: Integrator of Signaling via Hexosamine Flux
by: Mana Mohan Mukherjee, et al.
Published: (2025-07-01)

The Role of Cystatin C and Galectin-3 in Cardiorenal Syndrome
by: Nazar Ahemd Naji, et al.
Published: (2023-02-01)

Galectin-9: diverse roles in skin disease
by: Lin Wang, et al.
Published: (2025-07-01)

Leveraging AI to optimize galectin-3 inhibitors for Alzheimer’s disease: How to move forwards
by: Huiyong Zhang, et al.
Published: (2025-08-01)

AI-driven discovery of brain-penetrant Galectin-3 inhibitors for Alzheimer's disease therapy
by: Xueyan Liu, et al.
Published: (2025-08-01)

Possible Contribution of the Basal Ganglia Brainstem System to the Pathogenesis of Parkinson’s Disease
by: Takakusaki, Kaoru, et al.
Published: (2011)

GALECTIN 3 AND ALDOSTERONE IN PATIENTS WITH ATRIAL FIBRILLATION AND METABOLIC SYNDROME
by: V. A. lonin, et al.
Published: (2015-04-01)

Elevated expression of galectin-3 in excessive scars: A pilot study
by: Victor Freire Salomão Ferreira, et al.
Published: (2024-10-01)

Serum and Urine Galectin-3 as a Diabetic Nephropathy Predictive Biomarker
by: Dalia M. Saleh, et al.
Published: (2025-07-01)

Galectin-3 and structural and functional left ventricular characteristics in coronary artery disease in combination with chronic kidney disease
by: S. S. Fateev, et al.
Published: (2024-02-01)

Galectins: a potential pharmacological target
by: V. A. Serebryakova, et al.
Published: (2024-10-01)

NO: a key player in microbiome dynamics and cancer pathogenesis
by: Seyedeh Kimia Jasemi, et al.
Published: (2025-06-01)

Non‐human primate models of Parkinson's disease: Decoding pathogenesis and advancing therapies
by: Sihui Zhang, et al.
Published: (2025-06-01)

Diagnostic value of galectin-3 in heart transplant recipients with myocardial complications
by: O. P. Shevchenko, et al.
Published: (2020-04-01)

GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION
by: Yu. V. Dubolazova, et al.
Published: (2017-02-01)

The level of galectin-3 in the blood serum of patients with chronic hepatitis C
by: V. A. Kovalevа, et al.
Published: (2016-07-01)

Galectin-3 in recipients with kidney graft dysfunction: analysis of predictive significance
by: D. A. Velikiy, et al.
Published: (2024-09-01)

Renin–Angiotensin System Autoantibody Network in Parkinson’s Disease Patients
by: Carmen M. Labandeira, et al.
Published: (2025-06-01)

Galectin-3 as a Marker of Cardiorenal Syndrome in Patients with Chronic Heart Failure
by: V. I. Podzolkov, et al.
Published: (2022-05-01)

Galectin-3 inhibition ameliorates hepatic steatosis in a multilineage 3D spheroid model
by: Francesca Sedda, et al.
Published: (2025-01-01)

PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 MEASUREMENT IN PATIENTS WITH METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE
by: O. M. Drapkina, et al.
Published: (2015-10-01)

GALECTIN-3 LEVEL IN pATIENTS WITH mETAbOLIC SYNDROmE AND CORONARY HEART DISEASE
by: O. М. Drapkina, et al.
Published: (2017-03-01)

Gene Therapy for Parkinson’s Disease: Towards Non Invasive Approaches
by: Rodríguez, Manuel, et al.
Published: (2011)

Brain-derived extracellular vesicles: A promising avenue for Parkinson’s disease pathogenesis, diagnosis, and treatment
by: Shurui Zhang, et al.
Published: (2026-04-01)

Galectin-3 in solid organ recipients: role in graft pathology and prospects for use
by: D. A. Velikiy, et al.
Published: (2023-07-01)